Drug Profile
SH 306
Latest Information Update: 12 Jul 2002
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Reperfusion injury; Thrombosis
Most Recent Events
- 25 May 1998 New profile
- 25 May 1998 Preclinical development for Reperfusion injury in USA (Unknown route)
- 25 May 1998 Preclinical development for Thrombosis in USA (Unknown route)